Key Words: endoglin ◼ fibrosis ◼ growth differentiation factor 2 ◼ heart failure ◼ transforming growth factor beta Sources of Funding, see page 525 BACKGROUND: Heart failure is a growing cause of morbidity and mortality worldwide. Transforming growth factor beta (TGF-β1) promotes cardiac fibrosis, but also activates counterregulatory pathways that serve to regulate TGF-β1 activity in heart failure. Bone morphogenetic protein 9 (BMP9) is a member of the TGFβ family of cytokines and signals via the downstream effector protein Smad1. Endoglin is a TGFβ coreceptor that promotes TGF-β1 signaling via Smad3 and binds BMP9 with high affinity. We hypothesized that BMP9 limits cardiac fibrosis by activating Smad1 and attenuating Smad3, and, furthermore, that neutralizing endoglin activity promotes BMP9 activity.
H eart failure (HF)
1 is a growing public health problem expected to affect >10 million individuals in the United States by 2037. 2, 3 Cardiac fibrosis is an independent predictor of overall mortality, sudden cardiac death, HF death, and HF hospitalization independent of left ventricular ejection fraction. [4] [5] [6] Cardiac fibroblasts increase extracellular matrix synthesis, which exaggerates mechanical myocardial stiffness, disorganizes contraction because of myocyte separation, disrupts electronic connectivity, and worsens tissue hypoxia. [7] [8] [9] [10] Cardiac fibrosis remains a significant target of therapy for patients with HF, and signaling pathways that govern cardiac fibroblast activity remain a significant knowledge gap in our understanding of cardiac remodeling.
One of the most potent profibrogenic cytokine systems governing cardiac fibrosis is the transforming growth factor beta (TGFβ) superfamily, which includes TGF-β1 and 22 distinct bone morphogenetic proteins (BMPs). [11] [12] [13] [14] TGF-β1 and BMPs bind directly to type II receptors (TβRII) that dimerize with and activate type I receptors (TβRI), also known as activin-like kinases (ALKs), for signal transduction via downstream effector proteins known as Smads. One of the major challenges when targeting TGF-β1 activity is that, in addition to promoting signaling down 1 pathway, TGF-β1 also activates counterregulatory pathways that serve to limit its own activity. A classic example of TGF-β1 counterregulation is mediated by ALK5/Smad3 and ALK1/Smad1 activity, which, respectively, promote and inhibit TGF-β1 activity in cardiac fibroblasts.
We recently reported that the TGF-β1 coreceptor endoglin (CD105) promotes TGF-β1 signaling by preferentially phosphorylating Smad3, stimulating collagen synthesis by cardiac fibroblasts, and increasing cardiac fibrosis in models of left or right heart pressure overload. 15 , 16 Recent reports identified that endoglin binds BMP9, also known as growth differentiation factor 2, with high affinity and is required for BMP9 signaling via Smad1 in endothelium. 17, 18 BMP9 specifically promotes activin receptor-like kinase 1 (ALK-1)-mediated phosphorylation of Smads-1/5/8, which bind to Smad4 and translocate to the nucleus to activate Smad-response elements in BMP gene targets, such as the inhibitors of differentiation (Id 1-3) in endothelium. [19] [20] [21] No studies have explored a functional role for BMP9 in cardiac fibroblasts or HF or studied an interaction between endoglin and BMP9 in cardiac fibrosis. With this background in mind, we hypothesized that BMP9 may limit cardiac fibrosis by promoting ALK1/Smad1 activity and, furthermore, that neutralizing endoglin activity may serve as a novel approach to promote BMP9 activity in HF.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure and may be obtained by contacting the corresponding author.
Reagents
Wild-type (WT) mice were obtained from Jackson Laboratories. Endoglin haploinsufficient (Eng +/-) mice were generously provided by Dr Michelle Letarte, University of Toronto and BMP9 -/-mice by Dr Se-Jin Lee, John Hopkins University. Western blot analysis was performed with antibodies directed at BMP9 (R&D Systems), GAPDH (Millipore), phosphorylated Smad1 (Cell Signaling), phosphorylated Smad3 (Cell Signaling), total Smad1 (Cell Signaling), and total Smad3 (Cell Signaling). For endoglin-or BMP9-silencing experiments, cells were exposed to 50 nmol/L human endoglin small interfering RNA (siRNA) (Ambion #145527), human BMP9 siRNA (Ambion #4392420), scrambled siRNA (negative control; Ambion #4390844), or GAPDH siRNA (positive control; Ambion # 4390850). To neutralize endoglin activity in human cardiac fibroblasts, we used TRC105 (Tracon Pharmaceuticals Inc), a human/mouse chimeric endoglin-neutralizing antibody that binds human endoglin with high affinity. To neutralize endoglin activity in murine studies, we used M1043 (Amgen Inc), a rat anti-mouse endoglin antibody. Activity of the neutralizing endoglin antibodies (M1043 and TRC105) has been previously validated by NolanSteveaux and colleagues 17 who demonstrated potent antiendoglin activity in endothelial cells where BMP9 is known to promote Smad1 phosphorylation in an endoglin-dependent manner. Additional reports have previously confirmed the anti-endoglin activity of M1043 or TRC105 in hepatic fibrosis, cancer, pulmonary hypertension, and HF. 15, [22] [23] [24] [25] 
Human Left Ventricular Tissue Sampling
For analysis of left ventricular (LV) BMP9 expression in patients with HF, viable LV free wall tissue was obtained from human subjects with end-stage HF (n=8) referred for LV assist device implantation. Nonfailing LV tissue obtained from the National Disease Research Interchange served as controls (n=8). All tissue was rinsed with sterile saline, immediately frozen in liquid
Clinical Perspective
What Is New?
• Cardiac fibrosis is a major component of maladaptive remodeling in the heart. • Levels of bone morphogenetic protein 9 (BMP9) are increased in patients with heart failure, and we report a new role for BMP9 as an endogenous inhibitor of cardiac fibrosis.
What Are the Clinical Implications?
• ), liver transaminase elevation ≥2 times the upper limit of normal, or perceived interference with standard clinical care were excluded from blood collection. Patients without obstructive coronary artery disease (at least 50% coronary artery stenosis) and preserved LV ejection fraction served as controls (non-HF; n=10). Circulating BMP9, procollagen type I C-peptide, carboxy-terminal telopeptide of type I collagen levels were analyzed using a commercially available enzyme-linked immunosorbent assay (BMP9, R&D Systems; procollagen type I C-peptide and carboxy-terminal telopeptide of type I collagen, Orion Diagnostica). Blood sample collection was performed in concordance with the National Institutes of Health, approved by the Institutional Review Board of Tufts Medical Center, and subjects gave informed consent. The specificity of BMP9 reagents used in our study was tested using the BMP9 enzymelinked immunosorbent assay and BMP9 antibody (R&D Systems; AF3879) and failed to identify any cross-reactivity for BMP10, growth differentiation factor 8, and growth differentiation factor 11 ( Figure IA and IB in the online-only Data Supplement).
BMP9 Expression and Activity in a Mouse
Model of Pressure Overload-Induced HF Adult, male, 12-to 14-week-old mice were used for all studies. Transverse aortic constriction (TAC) using a 27G needle generated LV pressure overload-induced HF as previously described.
16
C57 Bl/6 WT mice were subjected to TAC for 2 or 8 weeks to initially quantify cardiac BMP9 expression. For BMP9 loss of function studies, BMP9 -/-mice were generously provided by Se Jin Lee (Johns Hopkins Medical Center, Baltimore, MD) and subjected to TAC for 2 weeks. To further test whether recombinant murine BMP9 (rmBMP9) rescues cardiac fibrosis, WT mice were subjected to Sham operation or TAC for 4 weeks, then received daily intraperitoneal injections of vehicle or rBMP9 for 4 additional weeks with ongoing TAC-induced LV pressure overload for a total of 8 weeks of TAC. At the conclusion of each experiment, terminal hemodynamics were recorded using a LV conductance catheter as described 26 and LV tissue was obtained for biochemical and histological analysis.
Loss of Endoglin Expression and Activity Increases BMP9 Expression in Pressure Overload-Induced HF
To determine whether loss of endoglin activity rescues cardiac fibrosis and promotes BMP9 activity, WT mice were subjected to Sham operation or TAC for 4 weeks, then received twice weekly intraperitoneal injections of immunoglobulin G (IgG) isotype control antibody or a neutralizing endoglin antibody (Eng NAb at 15 mg/kg; M1043, Amgen Inc) for 4 additional weeks with ongoing TAC-induced LV pressure overload (total of 8 weeks of TAC). At the conclusion of each experiment, terminal hemodynamics were recorded using LV conductance catheter as described 26 and LV tissue obtained for biochemical and histological analysis.
Histological Evaluation of Cardiac
Hypertrophy, Fibrosis, and Myocardial Capillary Density LV collagen abundance was quantified by picrosirius red staining. Cardiomyocyte cross-sectional area and capillary density were quantified as previously described. 
Real-Time Quantitative Polymerase Chain Reaction
Total RNA was extracted from the LV with Trizol (Life Technologies) and converted to cDNA with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Polymerase chain reaction was performed in triplicate using 40 cycles at 94°C for 15 seconds, 60°C for 30 seconds, and 72°C for 30 seconds with an ABI Prism 7900 Sequence Detection System. Primers for 18S ribosomal RNA, endoglin, TGF-β1, β-myosin heavy chain, sarcoplasmic endoplasmic reticulum ATPase, type I collagen, and calcineurin were described previously. 16, 26 For primer sequences, see Table I in the online-only Data Supplement.
Immunoblotting
Total protein was extracted and quantified from tissue homogenates or cultured cells and immunoblot analysis was performed as previously described. 27 
Functional Studies in Human Cardiac Fibroblasts
Human cardiac fibroblasts were isolated from LV tissue harvested during cardiac surgery at Tufts Medical Center. For recombinant human BMP9 (rhBMP9) studies, human cardiac fibroblasts were stimulated with TGF-β1 at 10 ng/mL or rhBMP9 at 1 to 10 ng/mL. 13 For neutralizing antibody studies, human cardiac fibroblasts were pretreated with 0.5 ng/ mL Eng NAb (TRC105, Tracon Pharmaceuticals Inc) or control IgG isotype for 24 hours in fibroblast basal medium without supplementation before stimulation with TGF-β1 at 10 ng/ mL. For endoglin-or BMP9-silencing experiments, 50 nmol/L siRNA stock was dilated in Optimem (Invitrogen) and combined with Lipofectamine before exposure to cells. After 24 to 48 hours, cells were harvested for real-time quantitative polymerase chain reaction and Western blot analysis.
Statistics
All statistical analyses were performed using Graph Pad Prism v6 (Graph Pad Software, Inc). Comparison between 2 experimental groups was performed with the unpaired Student t
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test and for ≥3 groups with a 1-way ANOVA. P values <0.05 were accepted as statistically significant.
Study Approval
Animals were treated in compliance with the Guide for the Care and Use of Laboratory Animals (National Academy of Sciences). Animal protocols were approved by the Tufts Medical Center Institutional Animal Care and Use Committee. The Tufts Medical Center Institutional Review Board approved collection of human tissue for cell culture.
RESULTS

Increased BMP9 Expression in Human HF
To explore a role for BMP9 in HF, we first determined levels of BMP9 in LV samples from patients with advanced HF referred for implantation of a LV assist device. Control LV samples were obtained from postmortem subjects without HF (n=8/group). In comparison with controls, LV BMP9 expression was increased in patients with advanced HF at the time of LV assist device implantation ( Figure 1A and 1B). In a separate cohort of patients with HF referred for cardiac catheterization (n=45), plasma BMP9 levels were ≈3-fold higher in comparison with patients without HF (n=10) ( Figure 1C ). In our human HF cohort, we found that circulating BMP9 correlated with LV ejection fraction (Pearson r= -0.45, P=0.001; Figure II in the online-only Data Supplement) and not procollagen type I C-peptide levels (r= -0.12, P=0.49), carboxy-terminal telopeptide of type I collagen levels (r=0.26, P=0.13), or the ratio of procollagen type I C-peptide/carboxy-terminal telopeptide of type I collagen (r= -0.24, P=0.16).
Increased BMP9 Expression in Pressure Overload-Induced HF
To further explore whether BMP9 levels are increased in response to HF, WT mice were subjected to 2 and 8 Figure 1 . Bone morphogenetic protein 9 expression is increased in heart failure.
Representative immunoblots (A) and quantitation of bone morphogenetic protein 9 (BMP9) and β-actin LV protein expression in patients with advanced heart failure referred for left ventricular assist device implantation (HF; n=8) (B) in comparison with non-heart failure controls (non-HF; n=8). C, Plasma BMP9 levels measured by ELISA in patients with heart failure (HF; n=45) in comparison with non-heart failure controls (non-HF; n=10). D, LV BMP9 mRNA expression after 2 and 8 weeks of transverse aortic constriction (TAC). n=3 independent experiments. E and F, Representative immunoblots and quantitation of LV BMP9, LV GAPDH, and plasma BMP9 protein after 2 (n=4) and 8 weeks (n=5) of TAC in comparison with Sham-operated controls (n=4 
BMP9 Limits TGF-β1-Induced Type I Collagen Synthesis in Human Cardiac Fibroblasts
To explore which cells in the adult heart express BMP9, we isolated adult murine cardiomyocytes, cardiac fibroblasts, and endothelial cells. BMP9 was abundantly expressed by fibroblasts and endothelial cells, not cardiomyocytes ( Figure 2A ). Next, we tested the effect of rhBMP9 on TGF-β1-induced type I collagen synthesis in human cardiac fibroblasts and identified that, in comparison with TGF-β1 alone, costimulation with TGF-β1 and rhBMP9 reduced type I collagen mRNA and protein expression ( Figure 2B and 2C). To explore the effect of BMP9 on collagen synthesis by fibroblasts, we used a loss-of-function approach using siRNA. Silencing BMP9 expression increased type I collagen mRNA and protein expression with and without TGF-β1 stimulation in human cardiac fibroblasts ( Figure 2D and 2E). These data identify that BMP9 is expressed by cardiac fibroblasts and negatively regulates TGF-β1-induced type I collagen synthesis.
Loss of BMP9 Promotes Cardiac Fibrosis in TAC-Induced HF
To explore a functional role for BMP9 in HF, we used BMP9 null mice (BMP9 -/-) which have total body depletion of BMP9 and no known intrinsic cardiovascular abnormalities. 31, 32 After 2 weeks of TAC, both WT and BMP9 -/-mice exhibited increased LV and lung mass; however, BMP9 -/-mice had higher LV filling pressures and lower LV dP/dT max ( Table 2) . No difference was observed between WT and BMP9 -/-mice without TAC. In comparison with Sham controls, LV fibrosis, type I collagen mRNA, and protein levels were increased in both WT and BMP9 -/-mice after TAC with a greater increase in collagen levels in BMP9 -/-than in WT mice after TAC ( Figure 3A . These data identify that loss of BMP9 is associated with worsening HF, increased LV collagen levels, and increased LV levels of TGF-β1 after TAC.
Loss of BMP9 Promotes Smad3 and Limits Smad1 Signaling
To study the effect of BMP9 loss on downstream TGF-β1/BMP9 signaling effectors, we measured LV levels of phosphorylated Smad1 (pSmad1) and pSmad3; mRNA levels of inhibitor of differentiation 1 and 2 (Id1 and Id2) as markers of Smad1 activity; and plasminogen activator inhibitor-1 as a marker of Smad3 activity. In comparison with Sham controls, LV levels of pSmad1 were increased in WT, but not BMP9 -/-mice after TAC ( Figure 3D ). In comparison with Sham controls, 
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LV levels of pSmad3 were increased in both WT and BMP9 -/-mice after TAC. In comparison with WT mice, LV levels of pSmad3 were higher among BMP9 -/-mice after TAC ( Figure 3E ). Consistent with the reduced pSmad1 levels, LV mRNA levels of Id1 and Id2 were reduced among WT and BMP9 -/-mice after TAC with a greater loss of Id1 and Id2 among BMP9 -/-mice than among WT mice after TAC ( Figure 3F ). LV mRNA levels of plasminogen activator inhibitor-1, a marker of Smad3 activity, were higher in BMP9 -/-mice than in WT mice ( Figure 3F ). These data identify that loss of BMP9 reduces Smad1 signaling and promotes Smad3 signaling in HF.
Recombinant BMP9 Prevents Progression of Cardiac Fibrosis in HF
Based on the observation that rhBMP9 attenuates type I collagen synthesis in vitro and that loss of BMP9 activity promotes cardiac fibrosis, we next tested the hypothesis that treatment with rmBMP9 prevents progression of cardiac fibrosis in response to LV pressure overload. WT mice were subjected to 4 weeks of TAC and then randomly assigned to intraperitoneal administration of rmBMP9 at 72 ng/d (rmBMP9-TAC; n=10) or vehicle control (Veh-TAC; n=10) for an additional 4 weeks of TAC exposure. After 8 weeks of TAC, 90% of rmBMP9-TAC in comparison with 50% of Veh-TAC survived for analysis (P=0.24 for survival comparison). In comparison with Veh-TAC, rmBMP9-TAC mice demonstrated higher total body weight, lower LV and lung mass, lower LV filling pressures, and higher dP/dT max and min (Table 3 ). In comparison with Veh-TAC, treatment with rmBMP9 reduced LV fibrosis and type I collagen mRNA and protein levels ( Figure 4A through  4C ). In comparison with Veh-TAC, rmBMP9 treatment increased LV protein levels of pSmad1 and decreased levels of pSmad3 ( Figure 4D and 4E ). In comparison with Sham controls, LV mRNA levels of Id1 and Id2 were decreased in Veh-TAC mice, but unchanged in 
Reduced Endoglin Activity Increases BMP9 Levels in HF
We previously reported that loss of endoglin activity prevents fibrosis and preserves LV function among Eng +/-mice after TAC. Recent reports identified endoglin as a central mediator of BMP9 activity in endothelial cells. To explore an interaction between endoglin and BMP9 in cardiac fibroblasts or HF, we first silenced endoglin expression in human cardiac fibroblasts by using a siRNA approach and identified increased BMP9 protein levels from cell lysates with or without TGF-β1 stimulation (Figure 5A) . Using a second loss-of-function approach, we blocked endoglin activity in human cardiac fibroblasts by using a neutralizing anti-endoglin antibody (Eng NAb) and observed increased BMP9 protein levels with and without TGF-β1 stimulation ( Figure 5B ). To determine whether loss of endoglin promotes BMP9 expression in vivo, we subjected Eng +/-mice to TAC for 2 weeks. In comparison with Sham controls and WT mice, LV levels of BMP9 were increased among Eng +/-mice ( Figure 5C ). Collectively, these data suggest that loss of endoglin activity promotes BMP9 expression in human cardiac fibroblasts and in the LV after pressure overload-induced HF.
Neutralizing Endoglin Activity Increases BMP9 Levels and Prevents Progression of Cardiac Fibrosis in HF
We previously reported that reduced endoglin activity prevents cardiac fibrosis attributable to LV pressure overload. Recent data showing that BMP9 interacts with endoglin in endothelial cells led us to hypothesize that reducing endoglin activity blocks fibrosis through a 2-hit mechanism that involves attenuating TGF-β1/ Smad3 signaling and promoting BMP9/Smad1 activity. To test this hypothesis, adult, male WT mice were subjected to 4 weeks of TAC, then randomly assigned to treatment with Eng NAb (n=6) or IgG isotype control (IgG TAC; n=5) via twice weekly intraperitoneal injection. Following an additional 4 weeks of TAC, all mice 
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survived. LV and lung mass were reduced in mice receiving Eng NAb in comparison with IgG controls after TAC (Table 4) . Eng NAb treatment was not associated with the development of mucocutaneous arteriovenous malformations on gross examination, new gastrointestinal bleeding, or anemia. Eng NAb treatment reduced LV filling pressures and increased LV dp/dT max in comparison with IgG control after TAC. Eng NAb treatment also reduced LV fibrosis and type I collagen mRNA and protein levels ( Figure 6A through 6C ). In comparison with IgG TAC, Eng NAb treatment increased LV and circulating BMP9 protein levels after TAC, which was associated with enhanced pSmad1/Id1/Id2 and reduced pSmad3/plasminogen activator inhibitor-1 levels (Figure 6D . These data support that, much like treatment with rmBMP9, neutralizing endoglin activity increases LV BMP9 levels and activity, preserves LV function, reduces the progression of LV fibrosis, promotes Smad1, and attenuates Smad3 signaling after the development of HF. To determine whether the effect of neutralizing endoglin activity is dependent on BMP9, we treated BMP9 -/-mice with Eng NAb. After 2 weeks of TAC, BMP9
-/-mice treated with Eng NAb exhibited LV mass, lung mass, and filling pressures similar to BMP9 -/-mice ( Table 2) . LV type I collagen mRNA, protein expression, and Id1 and Id2 mRNA levels were similar in BMP9 -/-mice treated with Eng NAb in comparison with BMP9 -/-mice ( Figure  IVC through IVE in the online-only Data Supplement). These data indicate that the effect of Eng NAb on fibrosis and cardiac function after TAC is dependent on BMP9 expression.
DISCUSSION
Our central finding is that BMP9 expression is increased in patients with advanced HF, that it limits TGF-β1-induced collagen expression in human cardiac fibro- ORIGINAL RESEARCH ARTICLE blasts, and that promoting BMP9 activity attenuates cardiac fibrosis in a mouse model of HF. We further introduce a new role for endoglin as a negative regulator of BMP9 expression and determine that neutralizing endoglin activity increases BMP9 levels and activity, thereby limiting TGF-β1 signaling, type I collagen synthesis, and cardiac fibrosis ( Figure 7 ). Our findings have several important clinical implications. First, most studies involving BMP9 focus on developmental biology and vascular remodeling with limited data in cardiac remodeling. Our findings introduce a functional role for BMP9 as an endogenous inhibitor of collagen production and cardiac fibrosis in HF. Second, in contrast to prior studies, whereby directly limiting TGF-β1 activity attenuates Smad3 phosphorylation, our findings introduce BMP9 as a master switch regulating canonical TGF-β1 signaling by promoting Smad1 and limiting Smad3 activity in HF. Third, we previously reported that limiting endoglin activity attenuates cardiac fibrosis in HF by limiting TGF-β1 activity. Because TGF-β1 signaling is an established mediator of both reparative and reactive fibrosis, we speculate that BMP9 may play a role in both processes. 28 We now introduce a new mechanism whereby endoglin serves as an endogenous antagonist of BMP9 expression in HF. Collectively, these findings provide new mechanistic insight into BMP signaling in HF and identify multiple novel strategies to either directly deliver BMP9 or indirectly promote BMP9 expression as potentially new therapeutic approaches to limit cardiac fibrosis in HF.
BMP signaling has been implicated in the fibrosis of the kidney, lung, and liver. 24, [29] [30] [31] [32] [33] [34] To date, the only study exploring a role for BMPs in cardiac fibrosis focused on the potential antifibrotic effects of BMP7. 35 Despite initially promising data, recombinant BMP7 has not shown efficacy in treating lung, skin, or kidney fibrosis. More recently, administration of BMP9, also known as growth differentiation factor-2, was reported to increase Smad1 phosphorylation in vascular endothelium and to reverse pulmonary arterial hypertension in mice. 36 Homozygous knockout of ALK-1 or endoglin are embryonically lethal because of defects in heart and vessel development; however, BMP9 knockout (BMP9 -/-) mice are viable into adulthood. 37, 38 BMP9 expression in HF and a role for BMP9 in cardiac fibrosis remain unexplored.
We first identified that circulating and myocardial protein levels of BMP9 are increased in patients with advanced HF and in a mouse model of pressure overload-induced HF. Consistent with our mouse model of HF, circulating BMP9 levels correlated inversely with clinical LV ejection fraction. Little is known about cardiac expression of BMP9 in the adult heart, and no studies have explored BMP9 expression in HF. It is important to note that BMP9 mRNA levels were decreased after LV pressure overload in mice, suggesting posttranscriptional regulation of BMP9 protein levels in HF. Most of our understanding of BMP9 biology is derived from hepatocytes where BMP9 is produced as prepro-peptide that is converted to unprocessed pro-BMP9, which is proteolytically cleaved to form mature circulating BMP9. One potentially relevant protease known to regulate BMP9 processing is the endopeptidase furin whose levels are known to be increased in both acute and chronic HF. Future studies exploring whether furin regulates BMP9 levels in HF are required. 
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To explore a functional role for BMP9 in HF, we next determined that BMP9 is highly expressed by nonmyocyte populations in the heart including cardiac fibroblasts and endothelial cells. Using loss-of-function and gain-of-function approaches, we then identified that BMP9 attenuates TGF-β1-induced collagen expression in human cardiac fibroblasts. A role for BMP9/ALK-1 signaling remains controversial. Several studies support a profibrotic role for BMP9/ALK-1 in the liver by increasing expression of hepcidin, which inhibits absorption of hepatic iron, thereby leading to iron accumulation and subsequent fibrosis. Yet studies using whole-body conditional ALK-1 knockout mice or ALK-1 heterozygous mice support that loss of ALK-1 promotes fibrosis. We recently reported that, in comparison with WT controls, ALK-1 heterozygous mice exhibit impaired LV function, increased cardiac fibrosis, and reduced myocardial levels of pSmad1 after pressure overload-induced HF. 39 Our present findings are consistent with these studies by showing that loss of BMP9 in HF replicates the profibrotic phenotype associated with reduced ALK-1 activity.
There are several potential mechanisms by which a Eng NAb increases BMP9 levels and activity. First, prior studies have shown that neutralizing endoglin antibodies disrupt the ability of BMP9 to bind to endoglin. 17 As a result, endoglin-blocking antibodies may increase the availability of unbound BMP9. This observation is supported by our data showing that BMP9 protein levels are increased in the LV and circulation of mice treated with Eng NAb. Second, in contrast to IgG-treated WT mice, treatment with Eng NAb increased LV mRNA and protein levels of BMP9, suggesting that Eng NAb may increase BMP9 transcription. Third, levels of BMP9 are known to be highly regulated by endopeptidases. 40 Neutralizing endoglin activity may decrease endoprotease levels, thereby increasing levels of intact BMP9. Future studies are required to identify mechanisms by which neutralizing endoglin activity increases BMP9 levels.
BMP-targeted therapeutics for cardiac remodeling remains largely unexplored. Delivery of recombinant BMP7 limits fibrosis in models of heart or kidney injury, but, in these studies, BMP7 was shown to in- In contrast, we now show a direct effect of BMP9 on cardiac fibroblasts. Treatment with rBMP9 has also been previously shown to attenuate pulmonary hypertension. Given that BMP9 negatively regulates collagen expression in vitro and in vivo, we explored the therapeutic potential of delivering rBMP9 as an approach to limit progressive fibrosis by treating mice 4 weeks after induction of HF. In contrast to BMP9 -/-mice, rBMP9 treatment reduced cardiac fibrosis, increased pSmad1 levels, and reduced pSmad3 levels. However, rBMP9 as a therapeutic approach may be limited by pharmacokinetics requiring frequent dosing and the risk of promoting bone formation at injection sites. Based on recent studies identifying that BMP9 binds endoglin with high affinity and our prior studies showing that reduced endoglin activity limits cardiac fibrosis, we tested the treatment effect of a potent anti-endoglin antibody (M1043; Amgen Inc). Activity of the neutralizing endoglin antibodies used in our study . BMP9 signaling is attenuated by endoglin and limits cardiac fibrosis in heart failure. Left, Endoglin promotes cardiac fibrosis by facilitating TGF-β1 and inhibiting BMP9 signaling in heart failure. Middle, Loss of BMP9 activity promotes Smad3 dominant signaling and increases cardiac fibrosis. Right, Recombinant BMP9 or neutralizing endoglin activity increases BMP9 signaling, promotes Smad1 dominant signaling, and decreases cardiac fibrosis in heart failure. ALK-1 indicates activin receptor-like kinase 1; BMP9, bone morphogenetic protein 9; Eng, endoglin; NAb Eng, neutralizing endoglin antibody; rBMP9, recombinant BMP9; and TGF-β1, transforming growth factor beta.
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July 31, 2018 525 ORIGINAL RESEARCH ARTICLE myocardial BMP9 levels, limited cardiac fibrosis, reduced pSmad3 levels, and increased pSmad1 levels and signaling through Id1 and Id2. Although the activation of compensatory signaling pathways by cardiomyocyte dysfunction may underlie cardiac fibrosis, accumulating data suggest that excessive fibrosis driven by TGFβ-mediated signaling in fibroblasts is sufficient to cause ventricular dysfunction. 41, 42 Our study supports that reducing pSmad 3 levels and increasing pSmad 1 levels by promoting BMP9 signaling reduces fibrosis and improves systolic function.
These findings also have potentially important clinical implications for BMP9 inhibitors under investigation as adjunctive therapy in cancer. 15 For highly vascular malignancies targeting the ALK-1 activity to limit neovascularization of tumors is an emerging new therapeutic approach. 16 An anti-human ALK-1 antibody (PF-3446962) and a ligand trap that sequesters BMP9 (ALK-1-Fc; Dalantercept) have potential to systemically disrupt BMP9 signaling and are currently under clinical investigation. 43, 44 Our findings now suggest that attenuating BMP9/ALK-1 signaling promotes cardiac fibrosis and may impair cardiac function. Careful monitoring for cardiovascular complications is warranted, in particular, for patients at risk for developing HF.
Our study has several limitations. We used the BMP9 -/-mouse model with reduced total body expression of BMP9 and cannot distinguish if our observations are, in whole or in part, attributable to the loss of BMP9 expression in nonfibroblast cell populations. Recently, fibroblast-specific loss of Smad 3 signaling has been shown to protect against cardiac fibrosis.
41
Future studies using cell-specific knockouts of endoglin are required to determine the role of fibroblasts as mediators of endoglin/BMP9 interactions in cardiac fibrosis. In addition, in the rescue studies of established LV fibrosis, extracardiac effects of rBMP9 or Eng NAb administration may have modified the cardiac response to pressure overload-induced HF. Finally, studies were conducted in male mice only, thereby potentially limiting the applicability of our findings to the female sex.
HF is a significant and growing global health problem and a primary mode of death for millions of individuals, yet despite the clear importance of TGF-β1 signaling in maladaptive remodeling, no therapies specifically targeting TGF-β1 signaling exist. We have now identified an exciting new paradigm that implicates BMP9 as an endogenous inhibitor of TGF-β1 activity in HF. We further introduce that administration of rBMP9 or increasing BMP9 abundance by reducing endoglin activity enhances Smad1 signaling, rescues cardiac fibrosis, and improves cardiac function. Further investigation of strategies to promote BMP9 activity or reduce endoglin activity may lead to new approaches to selectively inhibit canonical TGF-β1 signaling and to improve the lives of millions living with HF.
